Trial Profile
Phase 2, Open-Label Extension Study to Assess Long-Term Safety and Tolerability of Enobosarm (GTx 024) in Postmenopausal Women With Stress Urinary Incontinence
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Enobosarm (Primary)
- Indications Stress incontinence
- Focus Adverse reactions
- Sponsors GTx
- 28 Feb 2024 Planned End Date changed from 30 Jun 2020 to 21 Sep 2018.
- 28 Feb 2024 Planned primary completion date changed from 30 Jun 2020 to 21 Sep 2018.
- 28 Feb 2024 Planned initiation date changed from 30 Jun 2018 to 28 Jun 2018.